BioSpace News Archive

4D Biomaterials is pleased to announce that the official launch of 4D Design™ will take place this month at Formnext 2022, the largest professional additive manufacturing convention in the world.

Zynex, Inc. announced that its board of directors approved a program to buy back $10.0 million of the Company’s common stock.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that clinical and real-world data from more than 70 abstracts will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place from Nov. 4-8, 2022.

Shanghai Henlius Biotech, Inc. (2696. HK) announced that its first self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (generic name: serplulimab injection), in combination with carboplatin and albumin-bound paclitaxel for the first-line treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC), has been approved by the National Medical Products Administration (NMPA).

The Lung Cancer Research Foundation is pleased to announce the addition of Antoinette J. Wozniak, MD, FACP, FASCO to its senior leadership team as its first Chief Scientific Officer.

The Global Single-Use Bioprocessing Market Size accounted for USD 21.98 Billion in 2021 and is estimated to achieve a market size of USD 84.12 Billion by 2030 growing at a CAGR of 16.1% from 2022 to 2030.

The Global Biopharmaceutical Market Size accounted for USD 389.6 billion in 2021 and is estimated to achieve a market size of USD 856.9 billion by 2030 growing at a CAGR of 13.9% from 2022 to 2030.

BioLabs and LabCentral were chosen as the winner of the 2022 Prix Galien USA Awards, a prestigious award often regarded as the “Nobel Prize in the life sciences industry.”

Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report third quarter 2022 financial results after the market closes on Thursday, November 10, 2022.

The Barbara Ann Karmanos Cancer Institute has partnered with more than 50 cancer organizations across the country to issue a call to action urging individuals, providers and insurers to increase access to and utilization of low-dose computed tomography scans for those at high risk for lung cancer.